DIBI

DIBI (Denying Iron to Bacterial Infections) is a synthetic, high-affinity iron-binding co-polymer developed by Fe Pharmaceuticals. It functions as an iron chelator that sequesters ferric iron (Fe3+), an essential nutrient required for the growth, metabolism, and virulence of bacterial pathogens as well as the proliferation of tumor cells. By limiting the bioavailability of iron, DIBI exerts broad-spectrum antimicrobial and antineoplastic effects. The drug is being developed in multiple formulations to address diverse indications: an inhaled version for respiratory infections in cystic fibrosis and pneumonia; an intravenous (IV) formulation for complicated urinary tract infections (cUTI) and solid tumors such as breast and colorectal cancer; an oral formulation for gastrointestinal infections; and a topical cream for wound healing and skin/soft tissue infections. In veterinary medicine, DIBI is in Phase 2 development as an otic solution for canine otitis externa. It has also demonstrated synergistic potential when used in combination with standard chemotherapy agents like cisplatin and doxorubicin.

Other names

Denying Iron to Bacterial Infectionsiron-binding co-polymer